6 completed, 2 active not recruiting, 2 terminated. 10 Phase 2, 4 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 6, Active not recruiting 2, Terminated 2 |
| Phase 3 | 4 | Completed 2, Active not recruiting 1, Terminated 1 |
| Phase 1 | 2 | Completed 2 |
Follow Prothya Biosolutions: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose-Response in PD and Safety of Cofact Under VKA Anticoagulation Cofact - Healthy Volunteers | Phase 1 / Phase 2 | Completed | Prothya Biosolutions | 69 | 2021-11-12 | 2024-04-08 |
| Add-on Intravenous Immunoglobulins in Early Myositis Immune Globulin Intravenous (Human), Placebo - Inflammatory Myopathy, Idiopathic, Dermatomyositis | Phase 2 / Phase 3 | Active not recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 44 | 2021-09-13 | 2026-02-27 |
| Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study) Convalescent plasma - COVID-19 | Phase 2 / Phase 3 | Terminated | Erasmus Medical Center | 86 | 2020-04-08 | 2022-04-01 |
| Apotransferrin in Patients With β-thalassemia human apotransferrin - β-thalassemia Intermedia | Phase 2 | Terminated | Prothya Biosolutions | 10 | 2019-03-21 | 2022-08-15 |
| Apotransferrin in Atransferrinemia Human apotransferrin - Congenital Atransferrinemia | Phase 2 | Active not recruiting | Prothya Biosolutions | 5 | 2010-12-01 | 2026-09-16 |
| C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema C1 inhibitor concentrate (C1-esteraseremmer-N) - Angioedema | Phase 2 / Phase 3 | Completed | Prothya Biosolutions | 6 | 2006-11-01 | 2009-05-04 |
| Kinetics, Efficacy and Safety of C1-Esteraseremmer-N C1 inhibitor concentrate - Hereditary Angioedema Type I, Angioneurotic Edema | Phase 2 | Completed | Prothya Biosolutions | 12 | 2005-09-01 | 2009-05-04 |
| Succinylated Human Serum Albumin (Suc-HSA) for HIV-1 Infection succinylated human serum albumin - HIV Infections | Phase 1 / Phase 2 | Completed | International Antiviral Therapy Evaluation Center | 6 | 2005-08-01 | 2007-04-24 |
| Study on Mannan Binding Lectin (MBL) Substitution in MBL-Deficient Children With Chemotherapy-Induced Neutropenia Mannan Binding Lectin (MBL), Mannan Binding Lectin - MBL-Deficient, Neutropenia | Phase 2 | Completed | Prothya Biosolutions | 12 | 2004-04-01 | 2007-08-30 |
| Kinetics, Efficacy and Safety of IVIG-L in Hypogammaglobulinemia Patients IVIG-L - Hypogammaglobulinemia | Phase 2 / Phase 3 | Completed | Prothya Biosolutions | 15 | 2001-05-01 | 2007-04-19 |
Angioedema (2) · Hereditary Angioedema Types I and II (2) · Acquired angioedema (1) · Agammaglobulinemia (1) · Anemia (1) · Antisynthetase syndrome (1) · COVID-19 (1) · Congenital atransferrinemia (1) · Dermatomyositis (1) · HIV Infections (1) · Iron Overload (1) · Myositis (1) · Neutropenia (1) · Polymyositis (1)
Immunoglobulins, Intravenous (1) · Mannose-Binding Lectin (1) · Sodium Chloride (1) · prothrombin complex concentrates (1)
Netherlands (9) · Germany (1) · Italy (1) · Spain (1)
M. M. Levi, Prof. Dr. (2) · Alberto Piperno, MD, PhD (1) · Bart Biemond, MD, PhD (1) · Bart Rijnders, MD, PhD (1) · H N Caron (1) · Jan Prins, MD PhD (1) · Joep MA Lange, MD PhD (1) · Katja Moser, MD (1) · Raffaella Mariani, MD, PhD (1) · Salah Hadi, MD (1) · T W Kuijpers, MD, PdD (1) · Thomas Bodewes, MD (1)